Search Results - Modupe Idowu

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Elevated adenosine signaling via adenosine A2B receptor induces normal and sickle erythrocyte sphingosine kinase 1 activity

    Elevated adenosine signaling via adenosine A2B receptor induces normal and sickle erythrocyte sphingosine kinase 1 activity by Kaiqi Sun, Yujin Zhang, Mikhail Bogdanov, Hongyu Wu, Anren Song, Jessica Li, William Dowhan, Modupe Idowu, Harinder S. Juneja, Jose G. Molina, Michael R. Blackburn, Rodney E. Kellems, Yang Xia

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease

    Multicenter, phase 1 study of etavopivat (FT-4202) treatment for up to 12 weeks in patients with sickle cell disease by Santosh L. Saraf, Robert Hagar, Modupe Idowu, Ifeyinwa Osunkwo, Kimberly Cruz, Frans A. Kuypers, R. Clark Brown, James Geib, Maria Ribadeneira, Patricia Schroeder, Eric Wu, Sanjeev Forsyth, Patrick Kelly, Theodosia A. Kalfa, Marilyn J. Telen

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Hypoxia-mediated impaired erythrocyte Lands’ Cycle is pathogenic for sickle cell disease

    Hypoxia-mediated impaired erythrocyte Lands’ Cycle is pathogenic for sickle cell disease by Hongyu Wu, Mikhail Bogdanov, Yujin Zhang, Kaiqi Sun, Shushan Zhao, Anren Song, Renna Luo, Nicholas Parchim, Hong Liu, Aji Huang, Morayo G. Adebiyi, Jianping Jin, Danny C. Alexander, Michael V. Milburn, Modupe Idowu, Harinder S. Juneja, Rodney E. Kellems, William Dowhan, Yang Xia

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients with Sickle Cell Disease: RISE UP Phase 2 Results

    A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients with Sickle Cell Disease: RISE UP Phase 2 Results by Modupe Idowu, Lucas Otieno, Bogdan Dumitriu, Clarisse L. C. Lobo, Swee Lay Thein, Biree Andemariam, Obiageli Nnodu, Adlette Inati, Alexander Glaros, Sara Teresinha Olalla Saad, Pablo Bartolucci, Raffaella Colombatti, Alì Taher, Miguel R. Abboud, Abdulafeez Oluyadi, Varsha Iyer, Ophelia Yin, Susan Morris, Amber M. Yates, Hui Shao, Spurthi Patil, Rolandas Urbstonaitis, Ahmar U. Zaidi, Wally R. Smith

    Published 2023
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression

    Elevated sphingosine-1-phosphate promotes sickling and sickle cell disease progression by Yujin Zhang, Vladimír Berka, Anren Song, Kaiqi Sun, Wei Wang, Weiru Zhang, Ning Chen, Chonghua Li, Qibo Zhang, Mikhail Bogdanov, Danny C. Alexander, Michael V. Milburn, Mostafa H. Ahmed, Lin Han, Modupe Idowu, Jun Zhang, Gregory J. Kato, Osheiza Abdulmalik, Wenzheng Zhang, William Dowhan, Rodney E. Kellems, Pumin Zhang, Jianping Jin, Martin K. Safo, Ah‐Lim Tsai, Harinder S. Juneja, Yang Xia

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Structural and Functional Insight of Sphingosine 1-Phosphate-Mediated Pathogenic Metabolic Reprogramming in Sickle Cell Disease

    Structural and Functional Insight of Sphingosine 1-Phosphate-Mediated Pathogenic Metabolic Reprogramming in Sickle Cell Disease by Kaiqi Sun, Angelo D’Alessandro, Mostafa H. Ahmed, Yujin Zhang, Anren Song, Tzu‐Ping Ko, Travis Nemkov, Julie A. Reisz, Hongyu Wu, Morayo G. Adebiyi, Zhangzhe Peng, Jing Gong, Hong Liu, Aji Huang, Y. Edward Wen, Alexander Wen, Vladimír Berka, Mikhail Bogdanov, Osheiza Abdulmalik, Leng Han, Ah‐Lim Tsai, Modupe Idowu, Harinder S. Juneja, Rodney E. Kellems, William Dowhan, Kirk C. Hansen, Martin K. Safo, Yang Xia

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: